Special Issue

State-of-the-Art Vaccine Design

Message from the Guest Editor

Research in vaccine design has made significant progress in recent years, leveraging innovative technologies to enhance their efficacy, safety, and accessibility. One major advancement is the use of nucleic acids, such as mRNA and DNA technology, to directly produce the desired antigen within the recipient's body. Next-generation vaccines, including viral vectors, protein subunits, and nanoparticle-based formulations, are being investigated to stimulate strong, long-lasting immune responses involving B- and T-cells. Computational biology and artificial intelligence are also revolutionizing vaccine design by identifying new antigen targets and optimizing vaccine candidates. Synthetic biology has an important role in developing new adjuvants and delivery systems to enhance vaccine effectiveness. We are inviting submissions for this Special Issue to showcase the latest developments in vaccine design. Research areas can cover all aspects related to advancing knowledge in vaccine development and improving their performance.

Guest Editor

Dr. D. William Provance, Jr.
Center for the Development of Technology in Health, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil

Deadline for manuscript submissions

30 June 2026

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/213997

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

MDPI